Edition:
United States

Northwest Biotherapeutics Inc (NWBO.OQ)

NWBO.OQ on NASDAQ Stock Exchange Capital Market

0.49USD
2 Dec 2016
Change (% chg)

$0.01 (+1.99%)
Prev Close
$0.48
Open
$0.47
Day's High
$0.51
Day's Low
$0.47
Volume
358,157
Avg. Vol
315,477
52-wk High
$4.77
52-wk Low
$0.32

NWBO.OQ

Chart for NWBO.OQ

About

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid... (more)
No analyst recommendations are available for NWBO.OQ.

Overall

Beta: 1.81
Market Cap(Mil.): $65.49
Shares Outstanding(Mil.): 123.69
Dividend: --
Yield (%): --

Financials

  NWBO.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.78 -- --
ROI: -- -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Northwest Biotherapeutics files for non-timely 10-Q

* Northwest Biotherapeutics inc files for non-timely 10-Q - sec filing Source text for Eikon: Further company coverage:

Nov 09 2016

BRIEF-Northwest Biotherapeutics Inc announces registered direct offering

* Northwest Biotherapeutics Inc announces registered direct offering

Oct 21 2016

BRIEF-Northwest Biotherapeutics enters letter agreement with Cognate Bioservices

* Entered letter agreement with Cognate Bioservices relating to institutional financing of Cognate

Oct 19 2016

BRIEF-Northwest Biotherapeutics files for mixed shelf offering

* Files for mixed shelf offering of up to $150 million - SEC filing Source text for Eikon: Further company coverage:

Sep 23 2016

BRIEF-Northwest Biotherapeutics said Nasdaq accepts NW Bio Remediation Plan

* Nasdaq accepts NW Bio Remediation Plan for shares and warrants previously issued to Cognate Bioservices

Sep 06 2016

BRIEF-Northwest Biotherapeutics plans to use proceeds of offering for initiating Phase II clinical trials

* Entered into agreements with certain holders of offered warrants - SEC Filing

Aug 23 2016

BRIEF-Northwest Biotherapeutics says will sell to investors about 7.4 mln shares at 50 cents per share

* Entered into agreements with two new institutional investors for direct offering with gross proceeds of $3.7 million

Jul 05 2016

Earnings vs. Estimates